The endocannabinoid system, often shortened to ECS, is a signalling system in the body. It includes substances the body makes itself, receptors that can respond to those signals, and enzymes involved in making and breaking them down.
It helps explain why researchers study cannabis-derived cannabinoids. A biological mechanism describes a possible pathway; evidence about a particular product and patient still depends on the preparation and study.
The basic parts of the ECS
Endocannabinoids are signalling molecules made in the body. Two commonly discussed examples are anandamide and 2-arachidonoylglycerol (2-AG). Cannabinoid receptors include CB1 and CB2, although ECS signalling is broader than a two-receptor diagram. Enzymes help produce and break down endocannabinoids, which is part of how the system is regulated.
A 2016 review in Biological Psychiatry describes the endogenous cannabinoid system as a widespread signalling network and discusses its components and functions. A review is useful background synthesis. It does not show that changing one part of the system treats every condition associated with the ECS.
THC, CBD and the ECS
THC and CBD are plant cannabinoids, not endocannabinoids. THC is the cannabinoid most associated with intoxication and has been studied in controlled human experiments as well as clinical settings. CBD has a different pharmacology and a formulation-specific clinical evidence base, most clearly in certain licensed epilepsy medicines. Neither fact allows an ECS diagram to choose a product, predict response or bypass an individual clinical assessment.
For the source-specific detail, see THC, CBD and the broader cannabinoid reference.
ECS claims and patient outcomes
Mechanism language is often used as if it settles a practical question. It does not. A receptor finding, a cell experiment or an animal study may identify a plausible biological pathway, but it cannot establish benefit, safety, dose, suitability or the likely effects of a cannabis-based medicinal product in one person.
This is particularly important when the ECS is used to support broad claims about pain, mood, sleep, immunity or inflammation. The system is relevant to research in many areas; relevance is not the same as a proven treatment outcome. A sound article or label should name the exact preparation, population and study type before making a narrower claim.
ECS terms across MCPH
ECS language maps the research around a cannabinoid, terpene or product. Claims that something “supports the ECS” need the underlying study, preparation and population alongside them. The MCPH glossary explains the terms; the terpene reference and cannabinoid pages separate chemistry and laboratory work from human evidence.
For a prescribed medicine, questions about the product, other medicines or unwanted effects belong with the prescriber or pharmacist. The ECS does not replace that individual safety context.
Sources
- An Introduction to the Endogenous Cannabinoid System (PMID 26698193; DOI); narrative scientific review of ECS components and signalling; background synthesis, not treatment guidance.
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals (PMID 15173844); controlled human laboratory challenge, not a prescribed-product trial.
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome (PMID 28538134); randomised trial of purified CBD in a defined epilepsy population, not general CBD-product evidence.
- Medical cannabis (NHS); general UK patient context; it does not provide individual treatment guidance.
